Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05702827 · ClinicalTrials.gov registry record · Phase 3
Use of a Dual-agent Local Analgesic (Bupivacaine-meloxicam) for Abdominal Incisions in Patients Undergoing Retropubic Mid-urethral Sling Surgery
A Phase 3 study, sponsored by TriHealth.
- Completed
- Registry status
- Phase 3
- Development phase
- 148
- Enrollment target
NCT05702827 is a Phase 3 study that has completed, run by TriHealth. The registered enrollment target is 148 participants.
The verdict
NCT05702827, a Phase 3 study, has completed, sponsored by TriHealth.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 148 participants
- Enrollment target
Study Summary
This study will compare the use of a dual-agent local analgesic (bupivacaine-meloxicam) for abdominal incisions in patients undergoing retropubic mid-urethral sling surgery to see if narcotic usage and pain are impacted.
Interventions
- DRUG Bupivacaine-Meloxicam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2023-01-23 |
| Est. Completion | 2024-04-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05702827
The ClinicalTrials.gov registry entry for NCT05702827 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TriHealth, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bupivacaine-Meloxicam is the first listed.
NCT05702827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05702827 about?
NCT05702827 is a clinical study titled "Use of a Dual-agent Local Analgesic (Bupivacaine-meloxicam) for Abdominal Incisions in Patients Undergoing Retropubic Mid-urethral Sling Surgery". This study will compare the use of a dual-agent local analgesic (bupivacaine-meloxicam) for abdominal incisions in patients undergoing retropubic mid-urethral sling surgery to see if narcotic usage and pain are impacted.
What is the current status of trial NCT05702827?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 148 participants. The study started on 2023-01-23. Estimated completion is 2024-04-18.
What interventions are being tested in trial NCT05702827?
The interventions under investigation include: Bupivacaine-Meloxicam (DRUG).
Who is sponsoring clinical trial NCT05702827?
This trial is sponsored by TriHealth, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.